MetaCap

Emergent BioSolutions (EBS) vs Prelude Therapeutics (PRLD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prelude Therapeutics (PRLD) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 93.4% versus a loss of 49.7%. Over five years, PRLD leads with a -76.9% price change compared with -88.6% for EBS. Emergent BioSolutions is the larger company by market cap ($259.6 million vs $258.6 million), about 1.0 times the size, while Prelude Therapeutics is growing revenue faster (+73.4% vs -28.8%).

Emergent BioSolutions converts more of its revenue into profit, with a net margin of 7.1% versus -819.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EBS-49.70%PRLD+93.41%
+315%+121%-73%
Nov 21, 20251 yearNov 20, 2026
EBS-87.40%PRLD-77.66%
+37%-33%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EBS versus PRLD key metrics
MetricEBSPRLD
Share price$5.05$3.23
Market cap$259.65M$258.63M
1-day change-1.94%-0.77%
YTD return-59.14%+11.38%
1-year return-49.70%+93.41%
5-year return-88.58%-76.93%
Forward P/E4.83—
EPS (TTM)$-5.00$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$742.90M$12.14M
Revenue growth (YoY)-28.81%+73.43%
Net income (latest FY)$52.60M$-99.50M
Gross margin56.09%—
Operating margin13.47%-861.33%
Net margin7.08%-819.59%
52-week high$14.06$6.83
52-week low$4.36$1.30
Distance from 52-week high-64.08%-52.71%
Analyst consensusnonestrong_buy
Avg. price target upside+98.02%+172.45%
Average volume1.11M432.74K
Shares outstanding51.42M65.34M
Employees90079
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRLD has outperformed EBS by 143.1 percentage points over the past year.
  • Emergent BioSolutions is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -819.6 cents for Prelude Therapeutics.
  • Prelude Therapeutics grew revenue faster in its latest fiscal year (+73.43% vs -28.81%).

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

About Prelude Therapeutics

PRLD stock →

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

EBS vs PRLD FAQ

Which is bigger, Emergent BioSolutions or Prelude Therapeutics?

Emergent BioSolutions (EBS) is larger, with a market capitalization of $259.65M compared with $258.63M for Prelude Therapeutics (PRLD).

Which stock has performed better over the past year, EBS or PRLD?

PRLD returned +93.41% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.

Are Emergent BioSolutions and Prelude Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons